The clinical deployment of KRAS G12C inhibitors has delineated a class-specific toxicity profile characterized by on-target, off-tumor gastrointestinal (GI) effects and clinically significant organ-specific adverse events that necessitate vigilant, agent-specific monitoring. Here, KRAS is linked to neoplasm.